TIAA CREF Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

TIAA CREF Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$16.8M	Buy	196,120 +166,250	+557%	+$13.8M	0.01%	785
2018 Q4	$1.68M	Sell	29,870 -1,529	-5%	-$93.4K	﹤0.01%	2051
2018 Q3	$2.57M	Buy	31,399 +956	+3%	+$67.4K	﹤0.01%	1989
2018 Q2	$1.06M	Buy	30,443 +6,195	+26%	+$189K	﹤0.01%	2467
2018 Q1	$497K	Sell	24,248 -2,000	-8%	-$51.5K	﹤0.01%	2742
2017 Q4	$743K	Sell	26,248 -1,183	-4%	-$33K	﹤0.01%	2605
2017 Q3	$853K	Buy	27,431 +4,390	+19%	+$132K	﹤0.01%	2592
2017 Q2	$729K	Buy	23,041 +6,541	+40%	+$161K	﹤0.01%	2695
2017 Q1	$374K	Sell	16,500 -414	-2%	-$10.2K	﹤0.01%	2886
2016 Q4	$369K	Sell	16,914 -1,941	-10%	-$49.1K	﹤0.01%	2929
2016 Q3	$497	Hold	18,855	–	–	﹤0.01%	2846
2016 Q2	$372K	Buy	+18,855	New	+$367K	﹤0.01%	2979

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

TIAA CREF Investment Management's RETA Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 557% in Q1 2019, buying an estimated $13.8M and bringing the position to 196,120 shares worth $16.8M. The position accounts for 0.01% of the portfolio, ranked #785.

TIAA CREF Investment Management first reported a position in RETA in Q2 2016 and has held it in 12 quarters since. 157 funds tracked by Wall St. Rank hold RETA as of Q1 2019.

TIAA CREF Investment Management held 196,120 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $16.8M as of Q1 2019.
TIAA CREF Investment Management bought 166,250 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2019, an estimated $13.8M.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #785 holding.
TIAA CREF Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and has held it in 12 quarters since.
157 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.